How to Get Rezdiffra (Resmetirom) in Kentucky

What Is Rezdiffra and Why Does It Matter for Kentucky Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis, or MASH, with liver fibrosis. Before its March 2024 approval, no pharmacotherapy existed for this condition. Kentucky carries a significant burden of liver disease tied to obesity and metabolic syndrome, making access to this drug a pressing clinical question for patients and providers across the Commonwealth.

The drug works as a thyroid hormone receptor beta (THR-beta) agonist. It selectively activates THR-beta in the liver, reducing hepatic fat accumulation, inflammation, and fibrogenesis without causing systemic thyroid effects. In the MAESTRO-NASH trial (N=966), published in the New England Journal of Medicine in 2024, resmetirom 80 mg achieved NASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks, compared with 9.7% on placebo. The 100 mg dose produced resolution in 29.9% of participants. Fibrosis improvement by at least one stage occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group, versus 14.2% for placebo [1].

These numbers changed the treatment calculus for hepatologists. "Resmetirom represents the first pharmacologic option we can offer MASH patients beyond lifestyle modification," noted the American Association for the Study of Liver Diseases (AASLD) in its updated practice guidance.

Telehealth Prescribing: Getting Rezdiffra Without Leaving Home

Kentucky permits telehealth prescribing of Rezdiffra. This is a meaningful access point for patients in rural counties where hepatology specialists are scarce. The Kentucky Board of Medical Licensure allows physicians, nurse practitioners, and physician assistants to prescribe medications via synchronous audio-video visits, provided the prescriber holds an active Kentucky license or appropriate interstate compact credentials.

A telehealth visit for Rezdiffra typically follows the same clinical pathway as an in-person evaluation. The prescriber will review imaging (usually a FibroScan or MRI-PDFF), confirm a fibrosis stage of F2 or F3, check baseline labs, and assess contraindications. Patients in eastern Kentucky or other underserved regions can connect with hepatologists based in Louisville, Lexington, or even out-of-state providers licensed in Kentucky through telehealth platforms.

One practical consideration: some insurers require the initial visit to be in-person before authorizing ongoing telehealth follow-ups. Check your plan's telehealth policy before scheduling. HealthRX connects Kentucky patients with board-certified providers experienced in MASH management who can evaluate candidacy for resmetirom and handle prior authorization paperwork remotely.

Required Labs Before Starting Rezdiffra in Kentucky

Before any Kentucky prescriber writes a Rezdiffra prescription, a specific set of labs and diagnostics must be completed. This is not optional. The FDA prescribing information and payer prior authorization forms both demand documented baseline values.

The standard pre-treatment workup includes:

• ALT and AST to confirm active hepatic inflammation (most insurers require ALT above the upper limit of normal)
• Thyroid function panel (TSH, free T4) to rule out uncontrolled thyroid disease, since resmetirom acts on thyroid hormone receptors
• Hepatitis B and C serology to exclude viral hepatitis as the primary driver
• FibroScan (vibration-controlled transient elastography) or liver biopsy confirming fibrosis stage F2 or F3
• CBC and INR to screen for advanced liver disease or cirrhosis (F4 patients are excluded from the current indication)
• Lipid panel, because resmetirom significantly lowers LDL cholesterol, a secondary benefit tracked in MAESTRO-NASH where LDL fell by approximately 16% from baseline [1]

Kentucky has over 90 Quest Diagnostics and LabCorp locations, plus hospital-affiliated labs at UK HealthCare and Norton Healthcare, all capable of running this panel. FibroScan availability is more limited. The University of Kentucky Hepatology Clinic in Lexington and the University of Louisville GI Division both offer FibroScan. Several private gastroenterology practices in Bowling Green, Owensboro, and Northern Kentucky also have the device.

Turnaround time for labs is typically 1 to 3 business days. FibroScan results are available same-day. Expect the full diagnostic workup to take one to two weeks if scheduled efficiently.

Who Can Prescribe Rezdiffra in Kentucky?

Three categories of licensed clinicians can prescribe Rezdiffra in Kentucky: physicians (MD or DO), nurse practitioners (APRN), and physician assistants (PA). Kentucky grants APRNs full practice authority under KRS 314.011, meaning NPs can independently prescribe without a collaborative agreement. PAs in Kentucky still require a collaborative agreement with a supervising physician, though they can prescribe Schedule II through V substances and non-controlled medications including resmetirom.

In practical terms, most Rezdiffra prescriptions in Kentucky originate from hepatologists or gastroenterologists. This reflects the clinical complexity of MASH staging rather than any legal restriction. A primary care provider who is comfortable interpreting FibroScan results and managing liver-directed therapy can absolutely prescribe resmetirom and handle monitoring.

The prescriber must document the following in the medical record to satisfy both clinical standards and insurance requirements: confirmed MASH diagnosis (by biopsy or validated non-invasive testing), fibrosis stage F2 or F3, absence of decompensated cirrhosis, and baseline lab values. According to the AASLD's practice guidance on NAFLD/MASH, non-invasive testing algorithms combining FibroScan with serum biomarkers (FIB-4, APRI) may suffice for staging in many patients [2].

Pharmacy Access: Specialty and 503A Compounding Options

Rezdiffra is classified as a specialty medication. Most retail pharmacies (CVS, Walgreens, Kroger Pharmacy) do not stock it on their standard formulary shelves. Instead, it flows through specialty pharmacy channels.

The primary dispensing routes for Kentucky patients are:

Specialty pharmacies. Madrigal Pharmaceuticals has partnered with select specialty pharmacy networks for distribution. Patients typically receive shipments directly to their home via overnight courier. AllianceRx Walgreens Prime, Accredo (Express Scripts), and CVS Specialty are among the national specialty pharmacies that carry Rezdiffra. Kentucky patients can also use PANTHERx Specialty Pharmacy, which is headquartered in Pittsburgh but ships to Kentucky addresses [3].

503A compounding pharmacies. Kentucky's Board of Pharmacy licenses 503A compounding pharmacies to prepare patient-specific prescriptions. While resmetirom is a commercially available finished product (not typically a candidate for compounding), 503A pharmacies may compound it in specific clinical scenarios such as dose adjustments that are not available in the manufactured tablet strengths. Kentucky 503A pharmacies can ship within state lines. Patients should verify that any compounding pharmacy they use holds a current Kentucky Board of Pharmacy license.

Regardless of the dispensing route, expect a 7 to 14 day lead time between prescription submission and first delivery, primarily because of the prior authorization process rather than physical drug availability.

Prior Authorization: What Kentucky Insurers Require

Prior authorization is the single biggest bottleneck between a Kentucky patient and a Rezdiffra prescription. Every major commercial insurer operating in Kentucky (Anthem Blue Cross Blue Shield, Humana, Aetna, Cigna, UnitedHealthcare) requires PA for resmetirom.

A typical PA submission must include:

1. Documented MASH diagnosis with supporting evidence (biopsy pathology report, FibroScan with CAP and kPa values, or MRI-PDFF results)
2. Fibrosis stage F2 or F3, confirmed by validated assessment
3. Baseline labs (ALT/AST, TSH, hepatitis serologies, CBC)
4. Documentation that the patient has attempted lifestyle modifications (diet and exercise) for at least 3 to 6 months, depending on the payer
5. Prescriber specialty or attestation of hepatology expertise
6. Statement confirming absence of decompensated cirrhosis (Child-Pugh B or C)

PA turnaround varies. Anthem Kentucky processes most specialty drug PAs within 72 hours. Humana's specialty PA team in Louisville typically responds within 5 business days. If denied, patients have the right to appeal. The Kentucky Department of Insurance requires insurers to complete external reviews within 45 days for non-urgent cases.

Kentucky Medicaid does not cover Rezdiffra as of 2026. Patients enrolled in Kentucky Medicaid managed care plans (Humana CareSource, Anthem Medicaid, Aetna Better Health of Kentucky, Molina Healthcare, or WellCare of Kentucky) cannot obtain coverage through their plan. These patients should explore Madrigal's patient assistance program and copay card, which may cover the full cost for qualifying uninsured or underinsured individuals.

Cost and Financial Assistance Programs

The wholesale acquisition cost (WAC) of Rezdiffra is approximately $47,400 per year. That figure does not reflect negotiated rates between insurers and pharmacy benefit managers, but it gives patients a reference point for out-of-pocket exposure.

Madrigal Pharmaceuticals offers two financial assistance pathways. The first is a copay assistance card for commercially insured patients, reducing out-of-pocket costs to as low as $0 per month for eligible individuals, up to a maximum annual benefit. The second is a patient assistance program (PAP) for uninsured patients, providing Rezdiffra at no cost to those who meet income criteria.

Kentucky patients earning below 400% of the federal poverty level ($62,400 for a single individual in 2026) may qualify for the PAP. Applications require income documentation, proof of Kentucky residency, and a completed prescription from a licensed provider. According to data from the National Institutes of Health, medication assistance programs significantly improve adherence in patients with chronic liver disease, particularly among rural populations [4].

Monitoring and Follow-Up After Starting Rezdiffra

Once a Kentucky patient begins resmetirom, the prescriber must schedule follow-up labs and clinical assessments at defined intervals. The FDA label recommends checking liver function tests (ALT, AST, bilirubin) periodically during treatment. Most hepatologists in Kentucky follow a 12-week, then every-6-month monitoring schedule.

Thyroid function should be rechecked at 12 weeks and annually thereafter. While resmetirom is selective for the beta receptor and clinical trials showed no significant thyroid-axis disruption at therapeutic doses, vigilance is appropriate. In MAESTRO-NASH, the incidence of thyroid-related adverse events was similar between treatment and placebo groups (2.6% vs. 2.1%) [1].

The most common side effects reported in the trial were diarrhea (26.5% at the 100 mg dose vs. 16.8% placebo) and nausea (21.7% vs. 12.5%). These were generally mild, occurred early in treatment, and resolved without dose modification in most patients. Kentucky prescribers should counsel patients about GI symptoms during the first 4 to 8 weeks and emphasize that persistent or severe diarrhea warrants a clinical reassessment.

"Patients should understand that Rezdiffra is not a cure for MASH. It is a treatment that, combined with weight management and metabolic risk factor control, can halt or reverse fibrosis progression," stated guidance from the Endocrine Society on THR-beta agonists in metabolic liver disease [5].

Repeat FibroScan at 12 months can help assess treatment response. A decrease in liver stiffness measurement (LSM) by 20% or more from baseline suggests meaningful fibrosis improvement, according to published validation studies in Hepatology [6].

Transferring a Rezdiffra Prescription to Kentucky

Patients relocating to Kentucky or temporarily residing in the state can transfer an existing Rezdiffra prescription. Kentucky Board of Pharmacy regulations permit prescription transfers from any U.S. state for non-controlled substances. The process involves contacting the Kentucky specialty pharmacy, providing the transferring pharmacy's information, and allowing 3 to 5 business days for verification.

If the original prescription was written by an out-of-state provider, the prescription remains valid in Kentucky as long as the prescriber's license is active and the drug is FDA-approved. Some specialty pharmacies may require the patient to establish care with a Kentucky-licensed provider for ongoing refills and monitoring, particularly after the initial prescription period expires.

Patients transferring from a state where they received Rezdiffra through a compounding pharmacy should confirm that the new Kentucky pharmacy can source the same formulation. Differences in compounding ingredients (inactive excipients, capsule vs. tablet form) may affect tolerability.

Timeline: From First Visit to First Dose

The total elapsed time from a Kentucky patient's initial consultation to receiving their first Rezdiffra dose typically ranges from 3 to 6 weeks. Here is a realistic breakdown.

Week 1: Initial telehealth or in-person visit. Prescriber orders baseline labs and FibroScan.

Week 2: Labs and imaging completed. Results reviewed. If MASH with F2-F3 fibrosis is confirmed, prescriber submits the prior authorization request to the patient's insurer.

Weeks 3 to 4: Prior authorization review period. The prescriber's office responds to any payer requests for additional documentation.

Week 4 to 5: PA approved. Specialty pharmacy receives the prescription, verifies insurance, processes copay card enrollment, and ships the medication.

Week 5 to 6: Patient receives Rezdiffra and begins treatment.

Patients with straightforward cases and responsive insurers may complete this process in as few as 3 weeks. Denials and appeals can extend the timeline to 8 to 12 weeks. Starting the diagnostic workup before the first prescriber visit (by getting labs drawn through a PCP) can shave a full week off the process.